Focused Pharma

Focused Pharma is a clinical-stage pharmaceutical company specializing in the development of advanced therapies for Central Nervous System (CNS) disorders. The company's primary focus is on Attention Deficit Hyperactivity Disorder (ADHD), where it seeks to improve upon current stimulant treatments. Its lead product candidate, FP-001, is a novel prodrug of d-amphetamine engineered to provide a more stable therapeutic effect and a lower risk of abuse. By optimizing the delivery and metabolism of proven molecules, Focused Pharma aims to enhance patient outcomes and compliance. The company is currently progressing its lead program through early-stage clinical development to address significant unmet needs in the neuropsychiatry market.